We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.68B
1-Year Est. Return 375.52%
This Fund
S&P 500
This Quarter Est. Return
+40.89%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$1.68B
AUM Growth
-$49.5M
Cap. Flow
-$478M
Cap. Flow %
-28.49%
Top 10 Hldgs %
68.18%
Holding
41
New
5
Increased
6
Reduced
9
Closed
8

Top Buys

Rank Stock Value
1
TNGX icon
Tango Therapeutics
TNGX
+$55.6M
2
EDIT icon
Editas Medicine
EDIT
+$26M
3
EYPT icon
EyePoint Inc
EYPT
+$23.7M
4
IFRX icon
InflaRx
IFRX
+$13.7M
5
ASMB icon
Assembly Biosciences
ASMB
+$11.3M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$78.9M
2
SYRE icon
Spyre Therapeutics
SYRE
+$77.8M
3
RLAY icon
Relay Therapeutics
RLAY
+$72.6M
4
ERAS icon
Erasca
ERAS
+$51.4M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.36%
2 Financials 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
1
Relay Therapeutics
RLAY
$4.09B
$225M 13.37%
12,000,000
-5,000,000
-29% -$72.6M
ELVN icon
2
Enliven Therapeutics
ELVN
$4.21B
$166M 9.9%
3,275,000
– –
ALKS icon
3
Alkermes
ALKS
$7.62B
$157M 9.36%
3,000,000
-1,200,000
-29% -$46.9M
COGT icon
4
Cogent Biosciences
COGT
$5.93B
$118M 7.03%
3,050,000
+161,993
+6% +$5.67M
AMLX icon
5
Amylyx Pharmaceuticals
AMLX
$3.61B
$101M 6.04%
5,650,000
– –
DFTX
6
Definium Therapeutics
DFTX
$5.1B
$94.1M 5.6%
2,000,000
– –
SYRE icon
7
Spyre Therapeutics
SYRE
$7.66B
$75.2M 4.48%
846,786
-1,065,594
-56% -$77.8M
ANRO icon
8
Alto Neuroscience
ANRO
$1.34B
$71.9M 4.28%
2,723,196
– –
TNGX icon
9
Tango Therapeutics
TNGX
$4.05B
$70.3M 4.19%
+2,250,000
New +$55.6M
EYPT icon
10
EyePoint Inc
EYPT
$374M
$65.8M 3.92%
4,600,000
+1,775,000
+63% +$23.7M
TYRA icon
11
Tyra Biosciences
TYRA
$1.31B
$59.9M 3.57%
1,875,000
-600,000
-24% -$19.8M
DMRA
12
Damora Therapeutics
DMRA
$1.62B
$50.4M 3%
1,939,000
– –
CLDX icon
13
Celldex Therapeutics
CLDX
$3.05B
$50.2M 2.99%
1,350,000
-1,346,616
-50% -$43.5M
PHVS icon
14
Pharvaris
PHVS
$2.65B
$49.3M 2.93%
1,425,000
-493,970
-26% -$14.9M
LBRX
15
LB Pharmaceuticals
LBRX
$1.54B
$48.7M 2.9%
1,500,000
– –
ASMB icon
16
Assembly Biosciences
ASMB
$669M
$38.9M 2.32%
1,415,000
+415,000
+42% +$11.3M
EDIT icon
17
Editas Medicine
EDIT
$425M
$28.8M 1.72%
+8,889,000
New +$26M
KYMR icon
18
Kymera Therapeutics
KYMR
$9.6B
$28.7M 1.71%
250,000
-500,000
-67% -$43M
CATX icon
19
Perspective Therapeutics
CATX
$341M
$21.6M 1.29%
6,336,782
– –
IPSC icon
20
Century Therapeutics
IPSC
$368M
$21.3M 1.27%
8,695,652
– –
ZURA icon
21
Zura Bio
ZURA
$547M
$19.2M 1.14%
3,250,000
– –
AVTX icon
22
Avalo Therapeutics
AVTX
$977M
$18.8M 1.12%
1,018,319
+535,319
+111% +$8.46M
IFRX icon
23
InflaRx
IFRX
$308M
$16.4M 0.97%
+7,300,000
New +$13.7M
ANTX icon
24
AN2 Therapeutics
ANTX
$216M
$14.2M 0.85%
2,933,680
+599,967
+26% +$2.58M
NUVL
25
DELISTED
Nuvalent
NUVL
$12.3M 0.74%
100,000
-733,600
-88% -$78.9M
1
2

Similar funds

TNBTD
Trustmark National Bank Trust Department Jackson, Mississippi $1.68B AUM 19.26% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
SH
Spear Holdings Dubai, United Arab Emirates $1.68B AUM 4.3% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
HCA
Heck Capital Advisors Rhinelander, Wisconsin $1.67B AUM 26.33% 1-Year Est. Return

Commodore Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Commodore Capital held 41 positions worth $1.68B, down 2.9% from $1.73B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Commodore Capital withdrew a net $478M in Q2 2026, closing 8 positions and reducing 9 holdings. Its most notable exit was Erasca, an estimated $51.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Commodore Capital opened a new position in Tango Therapeutics worth $70.3M.

  • Commodore Capital's largest Q2 2026 buy was Tango Therapeutics: 2,250,000 shares worth $70.3M.
  • Commodore Capital added most to EyePoint Inc in Q2 2026, an estimated $23.7M increase.
  • Commodore Capital's biggest Q2 2026 reduction was Nuvalent, cutting an estimated $78.9M.
  • Commodore Capital fully exited Erasca in Q2 2026, selling an estimated $51.4M.
  • Commodore Capital's ten largest holdings make up 68% of its $1.68B portfolio in Q2 2026.
  • Commodore Capital opened 5 new positions and closed 8 in Q2 2026.
  • Commodore Capital's portfolio value fell 2.9% quarter-over-quarter to $1.68B.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.